COMPANY:

Bio-Techne

"Bio-Techne Corporation...today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811."

"Bio-Techne Corporation...announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community...'COMET enables the identification of multiple biomarkers and spatial interactions between different cell types within the TME'...'Its use together with Nucleai's AI spatial biomarker platform in predicting therapy response for patients enrolled in the SECOMBIT1 study, marks the first application of this innovative technology in a clinical trial, representing a significant step toward identifying predictive biomarkers.'..."

"Bio-Techne Corporation...announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research...Discovery's Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine."

"Bio-Techne Corporation...announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland."

"Bio-Techne Corporation...is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe."

"Bio-Techne Corporation...announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc."

"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's spatial biology division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology."

"Bio-Techne Corporation...announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California. Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools. We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year."

"Bio-Techne Corporation...has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR."

"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform."

"Bio-Techne Corporation...announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research...Spatial biology utilizes detailed tissue analysis and intracellular interactions to enable profound insights in cancer biology, immuno-oncology, and other research fields."

"Bio-Techne Corporation...announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to...cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology (AMP), to be held November 14-18 in Salt Lake City, Utah."

"Bio-Techne Corporation...announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023. The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET product suite, addressing complex biological questions from various research areas. COMET is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies, making panel design much more flexible and faster than any other hyperplex solution."

"Researchers at the University of Miami's Sylvester Comprehensive Cancer Center on Tuesday said they have been awarded a $2.5 million grant from the National Cancer Institute to develop an exosome-based prostate cancer test...The researchers will collaborate with Bio-Techne's Exosome Diagnostics to develop a more prostate cancer-specific platform based on the company's biomarker, the cancer center said in a statement."

"Bio-Techne...announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System...Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya."

"Bio-Techne Corporation...announced it has completed the acquisition of Lunaphore Technologies SA...Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets...Lunaphore's instrument portfolio includes COMET™, an end-to-end spatial biology platform, with tissue staining, imaging and image preprocessing steps integrated into a fully automated, high-throughput instrument, that delivers true walk-away automation with unmatched scalability, reproducibility, and retention of tissue morphology."

"Bio-Techne Corporation...announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024...Lunaphore's spatial biology technology enables the identification of biomarker 'signatures' with clinical relevance, providing data necessary to support the development of diagnostic tools and streamline clinical trials, and ultimately improve patient outcomes."

"Bio-Techne Corporation...announced that Exosome Diagnostics...has reported interim results from a previously published prospective, randomized study of more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period. This study adds to the body of published evidence on the ExoDx Prostate Test. The results came out in a peer-reviewed paper published today in Prostate Cancer and Prostatic Diseases."

"Bio-Techne...announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of a RNAscope multiomic workflow for the Standard BioTools Hyperion™ Imaging System...The new RNAscope HiPlex12 Flex Kit enables visualization of highly multiplexed RNA biomarkers using the Hyperion XTi or earlier models of the Hyperion Imaging System."

"Bio-Techne...announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells...RNAscope ISH Probes Kappa and Lambda are designed to detect immunoglobulin kappa and lambda light chains mRNA. RNAscope probes are visualized with the highly sensitive RNAscope ISH detection reagents, which are compatible with FFPE tissue."

"Bio-Techne...and Lunaphore...announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope™ in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases."

"Bio-Techne Corporation...announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida."

"Bio-Techne Corporation...announced that a newly finalized local coverage determination (LCD) from National Government Services, Inc., a Medicare Administrative Contractor, includes coverage for the ExoDx™ Prostate Test from Exosome Diagnostics, a Bio-Techne brand. The updated policy now covers an annual ExoDx Prostate Test for men who already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy. The coverage will go into effect March 1, 2023."

"Bio-Techne...announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV)."

"Nonagen Bioscience and Bio-Techne Corporation...announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience’s Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology...Nonagen Bioscience and Bio-Techne are targeting the last quarter of calendar 2022 to make Oncuria available as an LDT."

"Bio-Techne Corporation...announced that Exosome Diagnostics...will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orleans, LA. Exosome Diagnostics will have two poster presentations, including a podium presentation, six in-booth scientific presentations...Additional presentations include results of the ExoDx™ Prostate test clinical utility study as well as a 2.5 year follow-up and interim analysis of subjects who participated in the study and will conclude with the combined performance of the ExoDx Prostate test and MRI in the early detection of prostate cancer."

"Bio-Techne Corporation...announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome...The significance of this study is that in men with an EPI score below the cut-point of 15.6, the ExoDx Prostate test could prevent low-risk men from proceeding to radical prostatectomy."